durvalumab (imfinzi) fda approved for stage iii nsclc: standard of care? (bmic-024)
Published 6 years ago • 2.7K plays • Length 7:44Download video MP4
Download video MP3
Similar videos
-
1:36
fda approval of durvalumab for stage iii unresectable nsclc
-
2:43
fda approves durvalumab / imfinzi for resectable nsclc non-small cell lung cancer
-
0:57
dr. patel on the fda approval of durvalumab in nsclc
-
6:06
stage iii nsclc: when to start durvalumab
-
6:50
implications for using durvalumab in stage 3 nsclc
-
2:10
dr. langer on the benefit of durvalumab in stage iii nsclc
-
3:31
fda d.i.s.c.o. burst edition: fda approval of imfinzi (durvalumab) for adult patients with locall...
-
0:58
an expert’s thoughts on the fda approval of durvalumab in locally advanced lung cancers
-
4:43
treating for stage iii nsclc after progression on durvalumab
-
1:29
updated results for pacific trial establish new standard of care in lung cancer
-
4:37
durvalumab: a new option for stage iii nsclc patients? | davey daniel
-
8:16
case based panel discussion - stage 3 nsclc best schedule - durvalumab/imfinzi in varying patients
-
3:59
pacific trial of durvalumab for stage iii nsclc
-
3:53
[lung]the role of durvalumab in patients with stage 3 lung cancer in a real hospital
-
0:47
dr. feldman on durvalumab for patients with lung cancer
-
7:22
updated results on pacific trial: revise who should receive consolidation immunotherapy? (bmic-065)
-
1:01
impact of durvalumab as consolidation therapy in nsclc
-
1:24
durvalumab: the new standard of care for nsclc?
-
1:38
practical considerations for durvalumab in stage 3 nsclc